NCT04049617: Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors

NCT04049617
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Documented PD-L1 expression is only required for a biopsy substudy 
Exclusions: Patients who had prior treatment with an immune checkpoint inhibitor (anti-PD-1/ or PD-L1/2)
https://ClinicalTrials.gov/show/NCT04049617

Comments are closed.

Up ↑